论文部分内容阅读
目的:探讨同步放化疗治疗Ⅲ期非小细胞肺癌的临床疗效。方法:回顾性分析我院2009～2011年间收治的84例Ⅲ期非小细胞肺癌患者的临床资料,将其随机分为同步放化疗治疗组(即观察组,42例)和单纯化疗组(即对照组,42例),比较两组患者的临床疗效。结果:观察组患者经同步放化疗治疗后,CR7例,PR24例,SD8例,PD3例,治疗总有效率为73.8%,显著高于对照组的54.7%,治疗总有效率组间差异有统计学意义(P<0.05)。观察组患者发生骨髓抑制反应者28例(66.7%),消化道反应23例(54.8%),脱发34例(81.0%),对照组患者发生骨髓抑制反应者30例(71.4%),消化道反应26例(61.9%),脱发35例(83.3%),两组患者的不良反应发生率差异无统计学意义(P>0.05)。结论:同步放化疗治疗Ⅲ期非小细胞肺癌的临床疗效确切,毒副作用小,患者耐受性好,对提高Ⅲ期非小细胞肺癌患者的生存率具有重要的意义,值得临床进一步推广使用。
Objective: To investigate the clinical efficacy of concurrent chemoradiotherapy in the treatment of stage Ⅲ non-small cell lung cancer. Methods: The clinical data of 84 patients with stage Ⅲ non-small cell lung cancer admitted from 2009 to 2011 in our hospital were retrospectively analyzed. They were randomly divided into concurrent chemoradiotherapy group (42 cases) and chemotherapy alone group (ie, Control group, 42 cases), the clinical efficacy of two groups were compared. Results: The total effective rate was 73.8% in CR7, PR24, SD8 and PD3 in the observation group after treatment of concurrent chemoradiotherapy, which was significantly higher than that of the control group (54.7%). The total effective rate of the treatment group was statistically significant Significance (P <0.05). In the observation group, 28 cases (66.7%) had gastrointestinal reaction, 34 cases (54.8%) had gastrointestinal reaction, 34 cases (81.0%) had alopecia, 30 cases (71.4%) had bone marrow suppression reaction in the control group, There were 26 cases (61.9%) of reactions and 35 cases (83.3%) of hair loss. There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusions: The concurrent chemoradiotherapy for stage Ⅲ non-small cell lung cancer has definite clinical curative effect, small toxic and side effects and good patient tolerance. It is of great significance to improve the survival rate of patients with stage Ⅲ non-small cell lung cancer and is worth further promotion in clinic.